Compare TIC & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TIC | NEO |
|---|---|---|
| Founded | 1991 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Precision Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.1B |
| IPO Year | 2025 | 2008 |
| Metric | TIC | NEO |
|---|---|---|
| Price | $11.24 | $16.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 11 |
| Target Price | $12.64 | ★ $23.40 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,530,296,000.00 | N/A |
| Revenue This Year | $47.20 | $11.12 |
| Revenue Next Year | $6.28 | $9.68 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.36 | $7.07 |
| 52 Week High | $11.86 | $20.15 |
| Indicator | TIC | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 65.13 | 47.76 |
| Support Level | $8.87 | $15.73 |
| Resistance Level | N/A | $17.19 |
| Average True Range (ATR) | 0.56 | 0.87 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 84.46 | 41.78 |
TIC Solutions Inc is a provider of tech-enabled Testing, Inspection, Certification and Compliance (TICC), engineering, and geospatial services. It provides mission-critical services that are essential to the safety, reliability, and efficiency of industrial assets, buildings and public infrastructure. The company's services are often non-discretionary and are driven by regulatory requirements, customer risk management policies, and the need to extend the useful life of critical assets. It operates in North America and serve both public- and private-sector clients. Its public-sector clients include federal, state, and municipal agencies, public utilities, and environmental regulators. Its private-sector clients span industrial, infrastructure, construction, and real estate end markets.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.